Quarterly ResultMay 5, 2026, 04:15 PM
Contineum Therapeutics Q1 Net Loss $14.5M; Affirms Clinical Milestones
AI Summary
Contineum Therapeutics reported a net loss of $14.5 million for the first quarter of 2026, an improvement from $16.0 million in Q1 2025. The company affirmed key clinical development milestones, including positive topline data from its Phase 1b chronic pain trial for PIPE-791 and the initiation of the global Phase 2 PROPEL-IPF trial for PIPE-791. Contineum also highlighted Johnson & Johnson's ongoing Phase 2 trial for PIPE-307 in major depressive disorder and stated a cash runway through mid-2029.
Key Highlights
- Cash, cash equivalents, and marketable securities totaled $246.3 million as of March 31, 2026.
- Cash resources are sufficient to fund planned operations through mid-2029.
- Net loss for Q1 2026 was $14.5 million, down from $16.0 million in Q1 2025.
- Research and development expenses decreased 15% to $11.6 million in Q1 2026.
- General and administrative expenses increased 20% to $5.3 million in Q1 2026.
- Reported positive topline data from Phase 1b trial of PIPE-791 for chronic pain.
- Initiated patient dosing in global Phase 2 PROPEL-IPF trial for PIPE-791 in Q1 2026.
- Johnson & Johnson's Phase 2 Moonlight-1 trial for PIPE-307 in MDD is ongoing, estimated completion June 2026.